Read by QxMD icon Read


R Chakraborty, E Muchtar, S Kumar, F K Buadi, D Dingli, A Dispenzieri, S R Hayman, W J Hogan, P Kapoor, M Q Lacy, N Leung, M A Gertz
We compared overall survival (OS) of 1017 patients with newly diagnosed multiple myeloma (MM) who were treated with different novel agent-based induction regimens and who underwent early autologous stem cell transplant (ASCT). Subgroups were defined by type of induction therapy: cyclophosphamide-bortezomib-dexamethasone (CyBorD; n=193), bortezomib-dexamethasone (Vd; n=64), lenalidomide-dexamethasone (Rd; n=251), bortezomib-lenalidomide-dexamethasone (VRd; n=126), thalidomide-dexamethasone (Td; n=155) and vincristine-doxorubicin-dexamethasone or dexamethasone alone (VAD/Dex; n=228)...
August 22, 2016: Bone Marrow Transplantation
Lauren Tada, Humayun Anjum, W Kenneth Linville, Salim Surani
Recurrent pleural effusions occurring in association with immunoglobulin light chain amyloidosis and not associated with amyloid cardiomyopathy are rare. These portend an overall poor prognosis with mean survival time of approximately 1.8 months. We hereby report a case of a 59-year-old Caucasian female with recurrent pleural effusions and an ultimate diagnosis of pulmonary amyloidosis in association with plasma cell myeloma. The optimal treatment for recurrent pleural effusions in amyloidosis has not been determined; however, our patient responded to therapy with Cyclophosphamide-Bortezomib- (Velcade-) Dexamethasone (CyBorD) and had no repeat hospitalizations or recurrence of pleural effusion at four-month follow-up after initiation of therapy...
2015: Case Reports in Pulmonology
Nobuhiro Tsukada, Masahiro Ikeda, Sumito Shingaki, Kanji Miyazaki, Sohsuke Meshitsuka, Yumiko Yoshiki, Yu Abe, Kenshi Suzuki
Twenty-nine transplant eligible newly diagnosed multiple myeloma (NDMM) patients have received Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) as induction treatment in our institute since November 2011. CyBorD is composed of CPA 300 mg/m2 p.o., Bor 1.3 mg/m2 i.v. or s.c., and Dex 40 mg/body p.o. on days 1, 8, 15, and 22. The median number of CyBorD cycles was 4 (range 2-6), except in one patient who progressed during the first cycle. Grade 4 neutropenia was observed in 2 patients, but none experienced grade 2 thrombocytopenia...
August 2015: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
M Teresa Cibeira, Joan Bladé
No abstract text is available yet for this article.
July 30, 2015: Blood
Giovanni Palladini, Sajitha Sachchithanantham, Paolo Milani, Julian Gillmore, Andrea Foli, Helen Lachmann, Marco Basset, Philip Hawkins, Giampaolo Merlini, Ashutosh D Wechalekar
The combination of cyclophosphamide/bortezomib/dexamethasone (CyBorD) showed early promise of high rates of hematologic responses tempered by studies showing the inability to overcome poor prognosis of advanced cardiac amyloidosis. Large studies are needed to clarify its role in light chain (AL) amyloidosis. We report the outcome of 230 patients treated frontline with CyBorD. Overall hematologic response rate was 60%, and in the 201 patients with measurable disease it was 62%, with 43% achieving at least very good partial response (VGPR)...
July 30, 2015: Blood
R F Cornell, X Zhong, C Arce-Lara, E Atallah, L Blust, W R Drobyski, T S Fenske, M C Pasquini, J D Rizzo, W Saber, P N Hari
Recent studies support the use of bortezomib-based therapies in light chain amyloidosis (AL). We performed a retrospective analysis of the safety, efficacy and long-term survival (median follow-up 3 years) after bortezomib-based treatment in 28 consecutive patients with de novo AL deemed ineligible at initial presentation. The first 14 patients received bortezomib and dexamethasone (VD), and the second 14 patients received cyclophosphamide, bortezomib and dexamethasone (CVD; CyBorD). Both regimens were well tolerated with no treatment-related mortality...
July 2015: Bone Marrow Transplantation
N Areethamsirikul, E Masih-Khan, C-M Chu, V Jimenez-Zepeda, D E Reece, S Trudel, V Kukreti, R Tiedemann, C Chen
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) is a highly active three-drug induction regimen for untreated transplant-eligible multiple myeloma patients. Although CyBorD has been evaluated only in the phase 2 setting in a limited number of patients, its high efficacy and ease of administration have led to its widespread use. Given that clinical trial efficacy can overestimate real-life effectiveness, we reviewed our institutional experience with 109 newly diagnosed patients who were treated with CyBorD in a non-clinical trial setting...
March 2015: Bone Marrow Transplantation
Yoshitaka Kikukawa, Hiromichi Yuki, Sinya Hirata, Kazuhiko Ide, Hirotomo Nakata, Toshikazu Miyakawa, Naofumi Matsuno, Kisato Nosaka, Yuji Yonemura, Tatsuya Kawaguchi, Hiroyuki Hata, Hiroaki Mitsuya, Yutaka Okuno
Amyloid light-chain amyloidosis (ALA) is a rare disease with poor prognosis and is often associated with monoclonal gammopathy of undetermined significance, multiple myeloma, or Waldenström macroglobulinemia. Only high-dose melphalan with auto-peripheral blood stem cell transplantation (PBSCT) has shown high long-term hematological response rates, but combinations with novel agents, including bortezomib or lenalidomide, have recently shown high hematological response rates for AL amyloidosis patients. In the present study, we treated eight Japanese patients with AL amyloidosis using bortezomib, cyclophosphamide, and dexamethasone (CyBorD)...
February 2015: International Journal of Hematology
Yasunori Honda, Junko Inoue, Shinto Shingaki, Kanzi Miyazaki, Yu Abe, Eriko Sekine, Seiko Iki, Nobuhiro Tsukada, Kenshi Suzuki
A 53-year-old man initially presented with costalgia and was diagnosed with MM, based on the pathological findings. IgE monoclonal protein was detected by Serum protein electrophoresis (SPEP) and, surprisingly, IgE was elevated to 7,950,000 IU/ml. Monitoring the disease response during treatment, we employed quantification of serum M protein at SPEP, because IgE levels were found to be inaccurate and erratic. The patient was treated with CyBorD. He found injection site reactions to be very burdensome, due to extreme skin changes...
May 2014: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Gunjan Shah, Esha Kaul, Shelly Fallo, Furha Cossor, Hedy Smith, Kellie Sprague, Andreas Klein, Kenneth Miller, Raymond Comenzo
BACKGROUND: Bortezomib is a first-in-class proteasome inhibitor approved by the US Food and Drug Administration for the treatment of all phases of multiple myeloma (MM) and it is also used for the treatment of [corrected] light-chain amyloidosis (AL). The subcutaneous formulation of bortezomib was approved in 2012 based on data from Phase III studies in patients with relapsed MM. OBJECTIVE: This article reports experience with subcutaneous bortezomib in patients with newly diagnosed MM or AL in a tertiary care center...
October 2013: Clinical Therapeutics
Giampaolo Merlini
No abstract text is available yet for this article.
May 10, 2012: Blood
Rahma Warsame, Ingrid E Kohut, Angela Dispenzieri
POEMS syndrome is a rare paraneoplastic condition related to myeloma. Because it is rare, there is very little known about treatment options. The use of potentially neurotoxic chemotherapeutic drugs is of concern in a disease whose major manifestation is neuropathy. Herein, we describe an extraordinary response to the combination of cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in a patient with relapsed, life-threatening POEMS syndrome.
June 2012: European Journal of Haematology
Joseph R Mikhael, Steven R Schuster, Victor H Jimenez-Zepeda, Nancy Bello, Jacy Spong, Craig B Reeder, A Keith Stewart, P Leif Bergsagel, Rafael Fonseca
Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light chain amyloidosis (AL) before stem cell transplantation (ASCT), instead of ASCT in ineligible patients or as salvage. Treatment was a combination of bortezomib (1.5 mg/m2 weekly), cyclophosphamide (300 mg/m2 orally weekly), and dexamethasone (40 mg weekly). Seventeen patients received 2 to 6 cycles of CyBorD. Ten (58%) had symptomatic cardiac involvement, and 14 (82%) had 2 or more organs involved...
May 10, 2012: Blood
Meaghan L Khan, Craig B Reeder, Shaji K Kumar, Marthy Q Lacy, Donna E Reece, Angela Dispenzieri, Morie A Gertz, Phillip Greipp, Suzanne Hayman, Steven Zeldenhurst, David Dingli, John Lust, Stephen Russell, Kristina M Laumann, Joseph R Mikhael, P Leif Bergsagel, Rafael Fonseca, S Vincent Rajkumar, A Keith Stewart
Novel agents are considered standard components of induction therapy for newly diagnosed patients with multiple myeloma. We retrospectively compared the results of three consecutive phase 2 clinical trials; RD (lenalidomide/dexamethasone, n=34), CRD (cyclophosphamide/lenalidomide/dexamethasone, n=53) and CyBorD (cyclophosphamide/bortezomib/dexamethasone, n=63) (N=150). Response rates after four cycles of treatment were: ≥near complete response (nCR), 12% vs. 2% vs. 41%, P<0·0001 and very good partial response or better, 35% vs...
February 2012: British Journal of Haematology
C B Reeder, D E Reece, V Kukreti, C Chen, S Trudel, J Hentz, B Noble, N A Pirooz, J E Spong, J G Piza, V H J Zepeda, J R Mikhael, J F Leis, P L Bergsagel, R Fonseca, A K Stewart
We have studied a three-drug combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) on a 28-day cycle in the treatment of newly diagnosed multiple myeloma (MM) patients to assess response and toxicity. The primary endpoint of response was evaluated after four cycles. Thirty-three newly diagnosed, symptomatic patients with MM received bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8 and 11, cyclophosphamide 300 mg/m(2) orally on days 1, 8, 15 and 22 and dexamethasone 40 mg orally on days 1-4, 9-12 and 17-20 on a 28-day cycle for four cycles...
July 2009: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"